After successfully navigating the most intense week of earnings, Jim Cramer told his Mad Money viewers Friday that he's already looking forward to next week's trading action.
Cramer's game plan starts on Monday, with Advanced Micro Devices (AMD) - Get Advanced Micro Devices, Inc. Report and Cardinal Health (CAH) - Get Cardinal Health, Inc. Report . He said that while there's nothing wrong with AMD, the market seemingly has no love left for this stock. Cardinal Health may be an opportunity however, as the company can talk more about its most recent acquisition.
On Tuesday, Cramer will be watching CVS Health (CVS) - Get CVS Health Corporation Report , MasterCard (MA) - Get Mastercard Incorporated Class A Report , Mondelez (MDLZ) - Get Mondelez International, Inc. Class A Report and Apple (AAPL) - Get Apple Inc. Report , an Action Alerts PLUS holding. He said to wait and see what CVS and Mondelez have to say, but he'd be a buyer of Apple and MasterCard on any weakness.
Next, on Wednesday, it's Sprint (S) - Get SentinelOne, Inc. Class A Report , Kraft Heinz (KHC) - Get Kraft Heinz Company Report and Facebook (FB) - Get Meta Platforms Inc. Class A Report , another Action Alerts name, that will have Cramer's attention. When it comes to cell phones, T-Mobile US (TMUS) - Get T-Mobile US, Inc. Report is best in show according to Cramer. He said that Facebook is a buy on any weakness and he's waiting to hear what Kraft has in store.
Thursday brings earnings from Dunkin Brands (DNKN) - Get Dunkin' Brands Group, Inc. Report , a stock that's performing better than Starbucks (SBUX) - Get Starbucks Corporation Report , and Activision Blizzard (ATVI) - Get Activision Blizzard, Inc. Report , a stock Cramer said is definitely worth buying.
Finally, on Friday we will receive the latest non-farm payroll numbers. If the data are weak, the banks will get hammered, but if they're strong, look for all of the financials to rally.
Battle of the Titans: AMZN vs. GOOGL
After both companies reported strong earnings this week, Cramer asked the question that's on everyone's mind, who's better, Amazon.com (AMZN) - Get Amazon.com, Inc. Report or Alphabet (GOOGL) - Get Alphabet Inc. Class A Report ?
Cramer said that Amazon's conference call focused on what he called "faith-based investing," as the company talked only vaguely that India will be huge and that robots in their fulfillment centers will make a big difference.
As for Google, the company spoke of their dominant search business, of course, but also of their new cloud offerings that are growing like weeds. The company was able to fix their YouTube advertising problem, and Cramer noted that Google has billions overseas that could be repatriated under Trump.
So who's better? Cramer said that Google told the better story, but maybe that's only because Amazon, one of the greatest stock stories ever told, didn't have to.
Executive Decision: Western Digital
For his "Executive Decision" segment, Cramer spoke with Steve Milligan, CEO of Western Digital (WDC) - Get Western Digital Corporation Report , a stock that's doubled from last year's lows. The company just posted a 25-cents-a-share earnings beat.
Milligan said there are several secular drivers propelling their business, but they are also leveraged so that when things are good, they can be really good. On the flip side, he said, Western Digital is also better able to manage volatility than in years past.
When asked about those secular drivers, Milligan said that Western Digital's products serve a diverse set of customers, from consumers to enterprise, and most of the technology they produce is very challenging to make, which keeps supply growing slowly despite rampant demand.
When asked about Toshiba, Western Digital's partner for over 13 years that has fallen on hard times, Milligan said that they continue to help Toshiba solve their problems but are also looking to protect their own interests.
Finally, when asked about his financial allocation strategy, Milligan said that the first priority will always be reinvesting in their business to innovate and transform. They also remain committed to their dividend and to deleveraging their balance sheet whenever possible.
Executive Decision: AGCO
In his second "Executive Decision" segment, Cramer also spoke with Martin Richenhagen, president and CEO of AGCO (AGCO) - Get AGCO Corporation Report , a stock that's up 10% in 2017, after having posted a narrower-than-expected loss this quarter with strong guidance for the rest of the year.
Richenhagen said sales are picking up around the globe, including in the U.S., Europe and South America. He said Brazil looks better than last year and Argentina is also much stronger than before, but he remained skeptical about France, given the current political situation.
Richenhagen said that AGCO continues to innovate, and after unveiling new high-horsepower tractors earlier this year, they are now introducing new smaller tractors, all with modern designs.
When asked what new steel tariffs would mean for his company, Richenhagen said that investors must realize that protectionism needs to be paid for by someone and typically, that's customers.
Cramer said that the agriculture market continues to be strong and AGCO is among the best.
Executive Decision: BioMarin Pharmaceuticals
For his final "Executive Decision" segment, Cramer checked in with J.J. Bienaime, CEO of BioMarin Pharmaceuticals (BMRN) - Get BioMarin Pharmaceutical Inc. Report , a stock that's up 15% year-to-date.
Bienaime said that Brineura is the first drug approved to treat children with CLN2, a rare and devastating neurological degenerative disorder. It's estimated that between 1,200 and 1,500 patients around the world have the condition.
CLN2 begins with unexplained seizures, Bienaime said, and is often misdiagnosed. BioMarin is working hard to educate doctors about this disorder and plans to offer free genetic testing to young patients that have unexplained seizures.
When asked about Brineura's price tag of $480,000 per year, Bienaime said that developing new drugs comes with a lot of risk and most new drugs never make it to market. Those that do, like Brineura, come at a price of over $100,000 a year to manufacture, but for those whose only treatment option is Brineura, the drug is priceless.
In the Lightning Round, Cramer was bullish on Chevron (CVX) - Get Chevron Corporation Report , JPMorgan Chase (JPM) - Get JPMorgan Chase & Co. Report , Comcast (CMCSA) - Get Comcast Corporation Class A Report , Agilent Technologies (A) - Get Agilent Technologies, Inc. Report and Halliburton (HAL) - Get Halliburton Company Report .
Cramer and the AAP team tell their investment club members about five stocks they think look good this quarter, including Southwest (LUV) - Get Southwest Airlines Co. Report and Snap-On (SNA) - Get Snap-on Incorporated Report . Get in on the conversation with a free trial subscription to Action Alerts PLUS.
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
Top stories on TheStreet:
- Taking Apart Samsung's Galaxy S8 Beside an iPhone Shows How Picky Apple Is About Design
- 12 Brands Leading the Fattening Fast Food Delivery Revolution
- 5 Things We Learned From Daymond John of 'Shark Tank'
- LeBron James Reveals He Was Offered $10 Million to Sign With Reebok, But Still Decided on Nike
- 10 Summer Deals to Europe
At the time of publication, Cramer's Action Alerts PLUS had positions in SNA, LUV SBUX, AAPL, FB, WDC, GOOGL CMCSA.